Review
Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Emerging trends and persistent challenges in the management of adult syphilis

BMC Infectious Diseases201515:351

https://doi.org/10.1186/s12879-015-1028-3

©  Tuddenham and Ghanem. 2015

Received: 6 May 2015

Accepted: 15 July 2015

Published: 19 August 2015

Open Peer Review reports

Abstract

There are an estimated 10.6 million incident cases of syphilis worldwide each year. We highlight some persistent challenges and emerging trends in the clinical management of syphilis with a particular focus on therapy, serology, diagnostics, and prevention. Decades after the introduction of penicillin, the optimal management of early syphilis continues to be a controversial topic, particularly in the setting of HIV co-infection. Similarly, the need for routine lumbar puncture in HIV co-infected asymptomatic persons is an unanswered question. Despite advances in both automation and point-of-care diagnostics, we continue to rely on indirect measures of disease activity to manage this infection. As syphilis rates in some populations continue to rise, novel and effective prevention strategies are needed.

Keywords

Syphilis Treponema pallidum Neurosyphilis Therapy Diagnostics

Review

Worldwide, there are an estimated 10.6 million incident cases of syphilis each year [1]. Recent increases in rates of syphilis have been observed in high-income countries among men who have sex with men (MSM), many of whom are HIV co-infected [2–4]. While strict testing and treatment guidelines have significantly decreased morbidity and mortality of congenital syphilis in high-income countries, syphilis infection in pregnancy remains a significant cause of adverse pregnancy outcomes in many others [5, 6]. We were invited by the editors of BMC Infectious Diseases to contribute a review on current challenges in the management of syphilis. In this review,we highlight some emerging trends and persistent challenges in the clinical management of syphilis with a particular focus on therapy, serology, diagnostics, and prevention.

Therapy

Decades after the introduction of penicillin, the optimal management of early syphilis continues to be a controversial topic, particularly in the setting of HIV co-infection. Currently, most major clinical guidelines recommend similar treatment regimens for the various stages of syphilis (Table 1). Penicillin continues to be the drug of choice to treat all stages of syphilis in all populations with tetracyclines and cephalosporins acceptable alternate agents for some stages in non-pregnant persons [7]. In general, the emergence of drug resistance has precluded recommending macrolides for the routine treatment of early syphilis [8, 9].
Table 1

Treatment of syphilis: US, UK and European recommendations

Stage

US CDC- recommended regimens [11]

UK recommended regimens [10]

European recommended regimens [12]

US alternative regimens [11]

UK alternative regimens [10]

European alterative regimens [12]

Early syphilis (primary, secondary, early latent of <1-2 years’ duration

Benzathine penicillin G 2.4 million units IM single dose

Benzathine penicillin G 2.4 million units IM single dose or Procaine penicillin G 600 000 units IM q24h for 10 days

Benzathine penicillin G 2.4 million units IM single dose

Doxycycline 100 mg or PO q12h for 14 days Ceftriaxone 1-2 g IM q24h for 10 days

Doxycycline 100 mg or PO q12h for 14 days Erythromycin 500 mg or PO q6h for 14 days Ceftriaxone 500 mg IM or daily for 10 days Amoxicillin 500 mg PO q6h plus Probenecid 500 mg or po q6h for 14 days

Procaine penicillin 600 000 units IM or daily for 10-14 days Doxycycline 200 mg or daily orally for 14 days Ceftriaxone 500 mg-1 g IM or IV daily for 10 days Azithromycin 2 g orally single dose

Late syphilis (latent syphilis of >1-2 years’ duration, cardiovascular, gummatous syphilis

Benzathine penicillin G 2.4 million units IM weekly for 3 weeks

Benzathine penicillin G 2.4 million units IM or weekly for 3 weeks Procaine penicillin 600 000 units IM q24h for 17 days

Benzathine penicillin G 2.4 million units IM weekly for 3 dose

Doxycycline 100 mg PO q12h for 28 days

Doxycycline 100 mg or po q12h for 28 days Amoxicillin 2 g PO q8h plus probenecid 500 mg or po q6h for 28 days

Procaine penicillin 600 000 units IM or daily during 17-21 days Doxycycline 200 mg PO daily during 21-28 days

Neurosyphilis

Aqueous crystalline penicillin G 3-4 million units IV q4h for 10-14 days

Procaine penicillin 1.8-2.4 million units IM q24h plus probenecid 500 mg or po q6h for 17 days Benzyl penicillin 3-4 million units IV q4h for 17 days

Benzyl penicillin 3-4 million units IV q4h for 10-14 days

Ceftriaxone 2 g IM or IV q24h for 10-14 days

Doxycycline 200 mg po q12h for 28 days Amoxicillin 2 g PO q8h plus probenecid 500 mg or PO q6h for 28 days Ceftriaxone 2 g IM or IV q24h for 10-14 days

Ceftriaxone 1-2 g or IV daily during 10-14 days Procaine penicillin 1.2-2.4 million units IM daily and Probenecid 500 mg po q6h for 10-14days

IM: intramuscular, IV: intravenous, PO: by mouth, q4h: every 4 h, q6h: every 6 h, q12h: every 12 h, q24h: every 24 h, q48h: every 48 h, mg: milligrams, g: grams

Although most guidelines recommend similar treatment regimens for HIV-infected and uninfected persons with syphilis, debate has centered on whether enhanced therapy provides improved clinical or serological outcomes for HIV-co-infected persons [10–12]. The predilection for the development of early symptomatic neurosyphilis among HIV-infected persons [13, 14] and data showing that a single dose of 2.4 MU of benzathine penicillin G (BPG) may be insufficient to clear Treponema pallidum from the CSF of HIV-infected persons with early syphilis [15] have fueled this debate. Particular interest has focused on enhanced therapy using three intramuscular doses of 2.4 MU of BPG instead of one. In the pre-HIV era, three doses of 2.4 MU BPG were recommended as an alternate treatment regimen for neurosyphilis [16]. In the early 1980’s its use was abandoned, not because of lack of efficacy, but because it did not achieve consistent treponemicidal penicillin concentrations in the CSF [17]. Results of retrospective studies comparing one versus multiple doses of BPG were inconsistent [18]. The only published randomized controlled trial used a non-standard regimen for neurosyphilis. It was also underpowered to address the question in HIV-infected persons [19]. Recently, two studies tried to address the question. The first, a prospective multicenter Taiwanese study comparing 1 vs. 3 doses of BPG in HIV-infected patients, found no statistically significant differences in serological responses at 6 and 12 months between the two groups in the per protocol analysis, though a carry-forward analysis did suggest improved serological outcomes favoring the three dose group [20]. The second study, a retrospective review of 478 cases of early syphilis in HIV-infected patients followed in the US Military HIV Natural History Study, found no statistically significant difference in serologic response at 13 months in those receiving one dose of BPG versus those receiving ≥ 2 doses of BPG [21]. Neither study assessed clinical outcomes (e.g. development of early neurosyphilis) in a systematic way. As such, the question of enhanced therapy remains unanswered. Despite the fact that US guidelines are clear and unambiguous about single dose penicillin to treat early syphilis among HIV infected persons, many clinicians continue to use enhanced therapy [22].

Serologies

T. pallidum cannot be cultured in the laboratory and the performance characteristics of direct molecular diagnostics are limited [23–27]. Consequently, diagnosis and monitoring of treatment responses depend largely on serological testing. (The use of darkfield microscopy for the diagnosis of early syphilis using specimens from genital lesions, and the use of PCR testing on these lesions, which is even more sensitive, are rarely performed outside of specialized settings). The reliance on these indirect tests that may not necessarily reflect underlying disease activity has generated significant challenges in the management of syphilis [28].

The serofast state

Patients who fail to achieve a 4-fold (i.e. two-dilution) decline in nontreponemal [i.e. Venereal Diseases Research Laboratory (VDRL) or Rapid Plasma Reagin (RPR)] antibody titers, or those who have adequate serologic decline but do not completely revert from positive to negative have been referred to as ‘serofast’ [7]. The definition is broad and it is unclear if both categories should be grouped together. In this section, we define ‘serofast’ as those who do not achieve a four-fold decline in titers following stage-appropriate therapy [29].

The clinical importance of the serofast state was clearly documented in the pre-antibiotic era. During that time, 30 % of patients with early syphilis who were ‘Wasserman fast’ (the Wasserman test was a nontreponemal predecessor to the RPR and VDRL) developed late neurologic complications, though this was not seen in latent syphilis [30]. In the modern era, the optimal approach to managing a patient who fails to achieve a four-fold decline in nontreponemal antibody titers (and who was not reinfected) is not known. In one study, among 13 HIV-infected patients with serologic evidence of syphilis whose serologic titers failed to decline adequately a median of 287 days after therapy, 4 (31 %) were found to have CSF abnormalities consistent with asymptomatic neurosyphilis [31]. However another study did not find an increased frequency of CSF abnormalities in serofast HIV positive patients, but different definitions of serofast serologies were used [32].

In some cases, a longer duration of follow-up is necessary to document four-fold titer declines [33]. Indeed, persons with late syphilis [34] and those with HIV not on antiretroviral therapy exhibit slower serological responses [32]. Persons with a lower initial RPR may be more likely to remain serofast [29].

The short-term outcomes of treating patients who are serofast have been described. One study demonstrated that only a modest proportion (27 %) of HIV uninfected serofast patients with early syphilis achieved a serologic response 6 months after retreatment with one dose of 2.4MU BPG. There was no comparison group, so it is difficult to conclude that this response was solely attributable to retreatment [35]. Indeed, a study of patients with late latent syphilis found similar serological responses between treated and untreated serofast patients at the end of follow-up [33]. The more vexing problem lies beyond the short-term serological responses: What are the long-term clinical consequences of being serofast? At this time, the question remains unanswered. Nonetheless, current CDC guidelines recommend additional clinical and serological follow-up in serofast patients and retreatment if follow-up cannot be assured. Because treatment failure can be the result of unrecognized CNS infection, CDC guidelines further recommend that CSF examination be considered in these patients, if reinfection has been ruled out [11].

Diagnostics

Fully automated assays that detect treponemal antibodies and novel point-of-care (POC) diagnostics have significantly impacted the field of syphilis diagnostics.

The reverse sequence algorithm

Increased availability of automated testing has recently led many laboratories to switch to a reverse sequence algorithm (RSA) in which a treponemal test is conducted first, and if positive, followed by a confirmatory nontreponemal test [36]. Data on whether the RSA is cost effective in low prevalence settings are mixed, with one study from Canada finding that it was cost effective as compared with the traditional algorithm, and one study from the US finding that it was less cost effective [37, 38]. It does appear that the RSA may facilitate the identification of latent syphilis cases, though it may lead to more false positives as well [39–41].

The use of the RSA rather than the traditional nontreponemal-first algorithm does result in the identification of a number of patients with serodiscordant results (i.e. a positive treponemal test and a negative nontreponemal test) [36]. This can occur in the setting of 1) a false positive result, 2) early primary syphilis, 3) the prozone phenomenon, 4) adequately treated past syphilis or 5) untreated syphilis of long duration, as nontreponemal test titers may decline over time even in the absence of treatment. A second treponemal test (preferably based on different antigens than the original test) should be conducted to rule out the first possibility. Persons with a confirmed positive treponemal test and a negative nontreponemal test with a history of syphilis treatment will require no further management unless there is concern for reinfection [36].

Persons with serodiscordant serologies (i.e. confirmed positive treponemal and persistently negative non treponemal tests) and no history of syphilis treatment present several important clinical and public health questions, particularly since they would likely be missed by the traditional algorithm: What is their risk of transmitting syphilis sexually? What is their risk of transmitting syphilis vertically? What is their risk of progression to tertiary syphilis? Based on studies from the pre antibiotic era, the risk of sexual transmission in patients with late syphilis is low [42]. Vertical transmission of syphilis has been documented at around 10 % in mothers with late latent disease [43], while one study from 1922 reported that nearly 50 % of infants born to seronegative mothers had probable or definitive congenital syphilis [44]. However, the risk of vertical transmission in serodiscordant women in the antibiotic era when patients are often routinely exposed to beta lactam antibiotics, tetracyclines and macrolides for reasons other than syphilis treatment, combined with the use of significantly more sensitive modern nontreponemal tests is unknown. A recent retrospective review suggests that it is low [45]. The risk of progression to tertiary syphilis in serodiscordant patients in the modern antibiotic era is unknown and ethical and logistical challenges make it unlikely that a study to address this issue will be forthcoming. Two retrospective studies (Wohrl and Tuddenham) suggest that the risk of neurosyphilis at the time of discordant test results is low. The risk of ophthalmic syphilis may be higher, but the lack of objective measures for this diagnosis makes drawing conclusions difficult [46, 47].

In general, persons with serodiscordant results and no history of treatment should be assessed clinically, and treated appropriately if signs or symptoms of active syphilis are noted. If none are found, they should be treated for syphilis of unknown duration with three doses of 2.4MU of BPG weekly [48].

Point-of-care tests

Point of care (POC) tests are both simple and capable of providing rapid results to guide clinical decisions during the same encounter [49]. In recent years, a number of rapid POC tests, which can deployed in a variety of settings and provide results without specialized laboratory equipment, have been developed for syphilis [50–53]. These include treponemal tests, combination treponemal and nontreponemal tests, and multiplex tests that simultaneously test for syphilis antibodies and antibodies to other infections such as HIV and hepatitis C [50, 53–55]. The majority of these tests rely on lateral flow technology. Several are commercially available internationally. There is currently one which is FDA approved for use in the United States [52]. Recently, this test was granted a Clinical Laboratory Improvement Amendment (CLIA) waiver that will enable its use outside of traditional laboratory settings [56].

Efforts are underway to miniaturize current laboratory-based technologies to enable rapid enzyme linked immunosorbent assay (ELISA) tests to be run in the field. A recent paper reports on the development and deployment of a smartphone attachment, or “dongle,” which enables a triplex ELISA test that provides results for HIV, treponemal, and non-treponemal antibodies [57].

POC syphilis tests show considerable promise, however they do have some limitations. Most tests are based on treponemal antibodies and therefore cannot distinguish between new and previously treated infections. Combination treponemal and non-treponemal POC tests, which may offer more information, do not provide a non-treponemal titer with which to follow response to treatment. Therefore, in settings where laboratory access is available, POC tests may have less utility for general use. In settings where access to laboratory facilities is limited and where prevalence may be high, POC tests may play an integral role in the diagnosis of syphilis. An example is antenatal clinics, where the consequences of overtreatment may be relatively small, but the consequences of undertreatment may be catastrophic. A number of studies, including one large study in which POC’s were introduced in project sites in six countries demonstrated the feasibility of utilizing POC’s for antenatal screening in a variety of rural and urban settings, and significantly increased the proportion of pregnant women screened and treated for syphilis [58]. Mathematical modeling suggests that use of POC tests for antenatal syphilis screening in low resource settings is not only effective but cost effective as well [59].

Point of care syphilis testing in low resource settings may soon expand to include other specimens. Ho et al. optimized the “Syphicheck” POC test made by Qualpro Diagnostics, Goa, India, which was designed for use on blood to be used on CSF, and obtained results similar to those obtained with a CSF VDRL [60]. This could have important implications for the diagnosis of neurosyphilis in settings without extensive laboratory capabilities.

Neurosyphilis diagnostics

The diagnosis of neurosyphilis is challenging because there is no gold-standard diagnostic test. It requires a CSF examination, but the indications to perform this procedure remain an issue of debate. CDC guidelines currently recommend that a CSF examination be performed in 1) persons with neurologic signs or symptoms 2) persons diagnosed with tertiary syphilis (e.g. cardiovascular syphilis or late benign syphilis) and 3) asymptomatic persons whose serologic titers do not decline appropriately following recommended therapy [11]. This last recommendation remains the source of some controversy (as detailed above). The most controversial question is the need for a CSF examination in asymptomatic HIV-infected persons with CD4 cell counts ≤ 350 cells/mm3 or RPR titers ≥ 1:32. The last two criteria were noted to increase the probability of symptomatic and asymptomatic neurosyphilis in this population [31, 61]. At this time, data are lacking regarding the benefits of CSF examination in asymptomatic HIV-infected persons. Consequently, none of the major guidelines have adopted a formal recommendation for this population.

Once the CSF examination is obtained, interpreting the results may present further challenges. The CSF VDRL is the most specific test but it is only about 50 % sensitive. The CSF RPR is less sensitive than the CSF VDRL and should not be used for diagnosis of neurosyphilis [62]. CSF treponemal tests are more sensitive but less specific and a negative CSF treponemal test in the setting of a moderate to high pre-test probability of neurosyphilis does not rule out the diagnosis (reviewed by Harding) [63, 64]. The CSF pleocytosis in syphilis is lymphocyte predominant, and a cutoff of greater than or equal to 5 cells/ml has been standard; however this may have less specificity in HIV-infected persons [65].

Novel neurosyphilis diagnostics are being sought. Several papers have evaluated CSF CXCL-13, a B-cell chemoattractant, as a diagnostic test for neurosyphilis [66–68]. Marra et al. examined serum and CSF concentrations of CXCL-13 in 199 HIV-positive patients with early syphilis who were referred because of concern for neurosyphilis. The CSF concentration of CXCL-13 as well as a CSF: serum CXCL-13 ratio of >1 performed reasonably well compared to the CSF VDRL [66].

Public health interventions

Despite effective treatment and promising new diagnostics, syphilis rates have continued to increase in MSM, most significantly in HIV-infected MSM. A number of factors may be contributing to this, among them the practice of serosorting and seropositioning, often in place of conventional risk reduction preventive strategies such as condom use. In this setting the increased rates of unprotected anal intercourse, particularly in HIV positive men, may be contributing to transmission of syphilis and other STIs [69–71]. Given continued risk behaviors and increasing incidence of syphilis, new prevention strategies are needed. Some possible approaches include frequent screening, novel approaches to case finding, and consideration of chemoprophylaxis.

Frequent screening

Syphilis infection and reinfection rates in MSM and HIV infected MSM are high, and identifying and treating asymptomatic early infections may be important in breaking the chain of transmission [72, 73]. Annual screening of these populations has been shown to identify a significant number of asymptomatic infections [74]. However, other studies suggest that implementing more frequent screening in selected populations may have added benefits. One study in which routine syphilis serology was included with every blood test performed as part of HIV monitoring among HIV positive MSM attending a clinic in Australia found a marked increase in identification of early syphilis cases [75]. Furthermore, a study using mathematical models suggests that increasing the frequency of screening in certain high-risk target groups (such as MSM who have large numbers of partners or engage in group sex) to every 3 months may be critical to decreasing syphilis incidence [76]. Another model suggests that increased coverage and frequency of screening of HIV positive MSM may be cost effective [77]. Similarly, screening in incarcerated populations may be high yield, [78] and may be cost effective as well [79].

Case finding: novel approaches

The internet and mobile devices are increasingly being used to locate sex partners. New approaches that make use of the internet and mobile phone texting technologies to assist in partner notification, contact tracing, education, and testing must constantly evolve to reach at-risk groups [80–82]. Several studies have associated risk behaviors in MSM, including unprotected anal intercourse, with use of novel social networking applications [83, 84]. A recent report described increased syphilis testing with the use of a promotion campaign on the social networking site Grindr, which is often used by MSM to find sexual partners [85].

Antibiotic prophylaxis and other approaches

While mass antibiotic treatment, conducted in outbreak situations or high-prevalence settings, has had mixed results in affecting the incidence of syphilis [86, 87], targeted chemoprophylaxis of motivated high-risk individuals may be a reasonable strategy. A recent study demonstrated that over 50 % of MSM surveyed would be willing to take daily pills to decrease their risk of syphilis infection, and over 75 % were willing to take daily medication to decrease syphilis infections in the gay community. Mathematical modeling suggested that chemoprophylactic doxycycline, either widely distributed or targeted to certain high risk MSM, could significantly reduce new cases of syphilis in the MSM community, though cases would rebound once the intervention was stopped [88]. A recent pilot study showed the feasibility of daily doxycycline in a small group of high risk MSM. The study was not powered to show a difference in syphilis incidence, but there was a decrease in acute STIs in the group taking daily doxycycline [89]. This is an intriguing new approach, though larger studies will be required, and several important issues must be carefully weighed before moving forward, such as adherence, impact on the microbiome, emergence of drug resistance, and long-term drug toxicities. Finally, a recent study showed that male circumcision was associated with a decreased risk of incident syphilis in men and women [90].

Conclusions

Advances in diagnostics may have a significant impact on reducing cases of congenital syphilis in resource-limited settings, where rates of this devastating condition are still very high. Whether these diagnostics can have a meaningful impact on rising rates of syphilis among MSM is unclear. Without a vaccine in sight, novel and effective prevention strategies are sorely needed to combat this infection.

Declarations

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Johns Hopkins University School of Medicine
(2)
Division of Infectious Diseases

References

  1. Rowley J, Toskin I, Ndowa F. World Health Organization, Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections--2008 http://apps.who.int/iris/bitstream/10665/75181/1/9789241503839_eng.pdf.
  2. Patton ME, Su JR, Nelson R, Weinstock H, Centers for Disease Control and Prevention (CDC). Primary and secondary syphilis--United States, 2005-2013. MMWR Morb Mortal Wkly Rep. 2014;63(18):402–6.PubMedGoogle Scholar
  3. Read P, Fairley CK, Chow EP. Increasing trends of syphilis among men who have sex with men in high income countries. Sex Health 2015.Google Scholar
  4. Solomon MM, Mayer KH. Evolution of the syphilis epidemic among men who have sex with men. Sex Health 2014;12(2):96-102.Google Scholar
  5. Newman L, Kamb M, Hawkes S, Gomez G, Say L, Seuc A, et al. Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data. PLoS Med. 2013;10(2), e1001396.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Qin J, Yang T, Xiao S, Tan H, Feng T, Fu H. Reported estimates of adverse pregnancy outcomes among women with and without syphilis: a systematic review and meta-analysis. PLoS One. 2014;9(7), e102203.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Clement ME, Okeke NL, Hicks CB. Treatment of syphilis: a systematic review. JAMA. 2014;312(18):1905–17.View ArticlePubMedGoogle Scholar
  8. A2058G Prevalence Workgroup. Prevalence of the 23S rRNA A2058G point mutation and molecular subtypes in Treponema pallidum in the United States, 2007 to 2009. Sex Transm Dis. 2012;39(10):794–8.Google Scholar
  9. Lukehart SA, Godornes C, Molini BJ, Sonnett P, Hopkins S, Mulcahy F, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med. 2004;351(2):154–8.View ArticlePubMedGoogle Scholar
  10. Kingston M, French P, Goh B, Goold P, Higgins S, Sukthankar A, et al. UK National Guidelines on the Management of Syphilis 2008. Int J STD AIDS. 2008;19(11):729–40.View ArticlePubMedGoogle Scholar
  11. Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1–110.Google Scholar
  12. Janier M, Hegyi V, Dupin N, Unemo M, Tiplica GS, Potocnik M, et al. 2014 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol. 2014;28(12):1581–93.View ArticlePubMedGoogle Scholar
  13. Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS. 2008;22(10):1145–51.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Flood JM, Weinstock HS, Guroy ME, Bayne L, Simon RP, Bolan G. Neurosyphilis during the AIDS epidemic, San Francisco, 1985-1992. J Infect Dis. 1998;177(4):931–40.View ArticlePubMedGoogle Scholar
  15. Lukehart SA, Hook 3rd EW, Baker-Zander SA, Collier AC, Critchlow CW, Handsfield HH. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med. 1988;109(11):855–62.View ArticlePubMedGoogle Scholar
  16. Centers for Disease Control and Prevention (CDC). Syphilis: CDC recommended treatment schedules--1976. Obstet Gynecol. 1976;48(6):727–9.Google Scholar
  17. Mohr JA, Griffiths W, Jackson R, Saadah H, Bird P, Riddle J. Neurosyphilis and penicillin levels in cerebrospinal fluid. JAMA. 1976;236(19):2208–9.View ArticlePubMedGoogle Scholar
  18. Blank LJ, Rompalo AM, Erbelding EJ, Zenilman JM, Ghanem KG. Treatment of syphilis in HIV-infected subjects: a systematic review of the literature. Sex Transm Infect. 2011;87(1):9–16.View ArticlePubMedGoogle Scholar
  19. Rolfs RT, Joesoef MR, Hendershot EF, Rompalo AM, Augenbraun MH, Chiu M, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med. 1997;337(5):307–14.View ArticlePubMedGoogle Scholar
  20. Yang CJ, Lee NY, Chen TC, Lin YH, Liang SH, Lu PL, et al. One dose versus three weekly doses of benzathine penicillin G for patients co-infected with HIV and early syphilis: a multicenter, prospective observational study. PLoS One. 2014;9(10), e109667.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Ganesan A, Mesner O, Okulicz JF, O’Bryan T, Deiss RG, Lalani T, et al. A Single Dose of Benzathine Penicillin G Is as Effective as Multiple Doses of Benzathine Penicillin G for the Treatment of HIV-Infected Persons With Early Syphilis. Clin Infect Dis. 2015;60(4):653–60.View ArticlePubMedGoogle Scholar
  22. Dowell D, Polgreen PM, Beekmann SE, Workowski KA, Berman SM, Peterman TA. Dilemmas in the management of syphilis: a survey of infectious diseases experts. Clin Infect Dis. 2009;49(10):1526–9.View ArticlePubMedGoogle Scholar
  23. Gayet-Ageron A, Lautenschlager S, Ninet B, Perneger TV, Combescure C. Sensitivity, specificity and likelihood ratios of PCR in the diagnosis of syphilis: a systematic review and meta-analysis. Sex Transm Infect. 2013;89(3):251–6.View ArticlePubMedGoogle Scholar
  24. Gayet-Ageron A, Sednaoui P, Lautenschlager S, Ferry T, Toutous-Trellu L, Cavassini M, et al. Use of Treponema pallidum PCR in testing of ulcers for diagnosis of primary syphilis. Emerg Infect Dis. 2015;21(1):127–9.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Grange PA, Gressier L, Dion PL, Farhi D, Benhaddou N, Gerhardt P, et al. Evaluation of a PCR test for detection of treponema pallidum in swabs and blood. J Clin Microbiol. 2012;50(3):546–52.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Shields M, Guy RJ, Jeoffreys NJ, Finlayson RJ, Donovan B. A longitudinal evaluation of Treponema pallidum PCR testing in early syphilis. BMC Infect Dis. 2012;12:353-2334-12-353.View ArticleGoogle Scholar
  27. Tsang RS, Morshed M, Chernesky MA, Jayaraman GC, Kadkhoda K. Canadian Public Health Laboratory Network laboratory guidelines for the use of direct tests to detect syphilis in Canada. Can J Infect Dis Med Microbiol. 2015;26(Suppl A):13A–7.PubMedPubMed CentralGoogle Scholar
  28. Oboho IK, Gebo KA, Moore RD, Ghanem KG. The impact of combined antiretroviral therapy on biologic false-positive rapid plasma reagin serologies in a longitudinal cohort of HIV-infected persons. Clin Infect Dis. 2013;57(8):1197–202.View ArticlePubMedGoogle Scholar
  29. Sena AC, Wolff M, Martin DH, Behets F, Van Damme K, Leone P, et al. Predictors of serological cure and Serofast State after treatment in HIV-negative persons with early syphilis. Clin Infect Dis. 2011;53(11):1092–9.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Moore J, Padget P. The problem of seroresistant syphilis (so called Wasserman fastness). J Am Med Assoc. 1938;110:96–100.View ArticleGoogle Scholar
  31. Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms. Clin Infect Dis. 2009;48(6):816–21.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Gonzalez-Lopez JJ, Guerrero ML, Lujan R, Tostado SF, de Gorgolas M, Requena L. Factors determining serologic response to treatment in patients with syphilis. Clin Infect Dis. 2009;49(10):1505–11.View ArticlePubMedGoogle Scholar
  33. Ren RX, Wang LN, Zheng HY, Li J. No improvement in serological response among serofast latent patients retreated with benzathine penicillin. Int J STD AIDS 2015.Google Scholar
  34. Knaute DF, Graf N, Lautenschlager S, Weber R, Bosshard PP. Serological response to treatment of syphilis according to disease stage and HIV status. Clin Infect Dis. 2012;55(12):1615–22.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Sena AC, Wolff M, Behets F, Van Damme K, Martin DH, Leone P, et al. Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin. Clin Infect Dis. 2013;56(3):420–2.View ArticlePubMedGoogle Scholar
  36. Centers for Disease Control and Prevention (CDC). Discordant results from reverse sequence syphilis screening--five laboratories, United States, 2006-2010. MMWR Morb Mortal Wkly Rep. 2011;60(5):133–7.Google Scholar
  37. Chuck A, Ohinmaa A, Tilley P, Singh A, Jacobs P. Cost effectiveness of enzyme immunoassay and immunoblot testing for the diagnosis of syphilis. Int J STD AIDS. 2008;19(6):393–9.View ArticlePubMedGoogle Scholar
  38. Owusu-Edusei Jr K, Peterman TA, Ballard RC. Serologic testing for syphilis in the United States: a cost-effectiveness analysis of two screening algorithms. Sex Transm Dis. 2011;38(1):1–7.View ArticlePubMedGoogle Scholar
  39. Binnicker MJ, Jespersen DJ, Rollins LO. Direct comparison of the traditional and reverse syphilis screening algorithms in a population with a low prevalence of syphilis. J Clin Microbiol. 2012;50(1):148–50.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Gratrix J, Plitt S, Lee BE, Ferron L, Anderson B, Verity B, et al. Impact of reverse sequence syphilis screening on new diagnoses of late latent syphilis in Edmonton. Canada Sex Transm Dis. 2012;39(7):528–30.View ArticlePubMedGoogle Scholar
  41. Mishra S, Boily MC, Ng V, Gold WL, Okura T, Shaw M, et al. The laboratory impact of changing syphilis screening from the rapid-plasma reagin to a treponemal enzyme immunoassay: a case-study from the Greater Toronto Area. Sex Transm Dis. 2011;38(3):190–6.View ArticlePubMedGoogle Scholar
  42. Moore J. The Modern Treatment of Syphilis. Springfield, IL: Charles C. Thomas; 1943.Google Scholar
  43. Wicher V, Wicher K. Pathogenesis of maternal-fetal syphilis revisited. Clin Infect Dis. 2001;33(3):354–63.View ArticlePubMedGoogle Scholar
  44. Williams J. Influence of the treatment of syphilitic pregnant women on the incidence of congenital syphilis. Bulletin Johns Hopkins Hospital 1922;33(383):435-448.Google Scholar
  45. Peterman TA, Newman DR, Davis D, Su JR. Do women with persistently negative nontreponemal test results transmit syphilis during pregnancy? Sex Transm Dis. 2013;40(4):311–5.View ArticlePubMedGoogle Scholar
  46. Wohrl S, Geusau A. Neurosyphilis is unlikely in patients with late latent syphilis and a negative blood VDRL-test. Acta Derm Venereol. 2006;86(4):335–9.View ArticlePubMedGoogle Scholar
  47. Tuddenham S, Ghanem K. Neurosyphilis and Ophthalmic Syphilis in Persons with Negative Rapid Plasma Reagin and Positive Treponemal Antibody Tests. Sexually Trans Dis (In Press).Google Scholar
  48. Ghanem KG, Workowski KA. Management of adult syphilis. Clin Infect Dis. 2011;53 Suppl 3:S110–28.View ArticlePubMedGoogle Scholar
  49. Tucker JD, Bien CH, Peeling RW. Point-of-care testing for sexually transmitted infections: recent advances and implications for disease control. Curr Opin Infect Dis. 2013;26(1):73–9.View ArticlePubMedPubMed CentralGoogle Scholar
  50. Tucker JD, Bu J, Brown LB, Yin YP, Chen XS, Cohen MS. Accelerating worldwide syphilis screening through rapid testing: a systematic review. Lancet Infect Dis. 2010;10(6):381–6.View ArticlePubMedGoogle Scholar
  51. Kay NS, Peeling RW, Mabey DC. State of the art syphilis diagnostics: rapid point-of-care tests. Expert Rev Anti Infect Ther. 2014;12(1):63–73.View ArticlePubMedGoogle Scholar
  52. Gaydos C, Hardick J. Point of care diagnostics for sexually transmitted infections: perspectives and advances. Expert Rev Anti Infect Ther. 2014;12(6):657–72.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Bristow CC, Larson E, Javanbakht M, Huang E. Causer L. A review of recent advances in rapid point-of-care tests for syphilis. Sex Health: Klausner JD; 2015.Google Scholar
  54. Bristow CC, Adu-Sarkodie Y, Ondondo RO, Bukusi EA, Dagnra CA, Oo KY, et al. Multisite Laboratory Evaluation of a Dual Human Immunodeficiency Virus (HIV)/Syphilis Point-of-Care Rapid Test for Simultaneous Detection of HIV and Syphilis Infection. Open Forum Infect Dis. 2014;1(1):ofu015.View ArticlePubMedPubMed CentralGoogle Scholar
  55. Hess KL, Fisher DG, Reynolds GL. Sensitivity and specificity of point-of-care rapid combination syphilis-HIV-HCV tests. PLoS ONE. 2014;9(11), e112190.View ArticlePubMedPubMed CentralGoogle Scholar
  56. Food and Drug Administration: FDA Press Announcement: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426843.htm, Accessed 4/17/15.
  57. Laksanasopin T, Guo TW, Nayak S, Sridhara AA, Xie S, Olowookere OO, et al. A smartphone dongle for diagnosis of infectious diseases at the point of care. Sci Transl Med. 2015;7(273):273re1.View ArticlePubMedGoogle Scholar
  58. Mabey DC, Sollis KA, Kelly HA, Benzaken AS, Bitarakwate E, Changalucha J, et al. Point-of-care tests to strengthen health systems and save newborn lives: the case of syphilis. PLoS Med. 2012;9(6), e1001233.View ArticlePubMedPubMed CentralGoogle Scholar
  59. Kuznik A, Lamorde M, Nyabigambo A, Manabe YC. Antenatal syphilis screening using point-of-care testing in Sub-Saharan African countries: a cost-effectiveness analysis. PLoS Med. 2013;10(11), e1001545.View ArticlePubMedPubMed CentralGoogle Scholar
  60. Ho EL, Tantalo LC, Jones T, Sahi SK, Marra CM. Point-of-care treponemal tests for neurosyphilis diagnosis. Sex Transm Dis. 2015;42(1):48–52.View ArticlePubMedPubMed CentralGoogle Scholar
  61. Marra CM, Maxwell CL, Smith SL, Lukehart SA, Rompalo AM, Eaton M, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis. 2004;189(3):369–76.View ArticlePubMedGoogle Scholar
  62. Marra CM, Tantalo LC, Maxwell CL, Ho EL, Sahi SK, Jones T. The rapid plasma reagin test cannot replace the venereal disease research laboratory test for neurosyphilis diagnosis. Sex Transm Dis. 2012;39(6):453–7.View ArticlePubMedPubMed CentralGoogle Scholar
  63. Harding AS, Ghanem KG. The performance of cerebrospinal fluid treponemal-specific antibody tests in neurosyphilis: a systematic review. Sex Transm Dis. 2012;39(4):291–7.View ArticlePubMedGoogle Scholar
  64. Dumaresq J, Langevin S, Gagnon S, Serhir B, Deligne B, Tremblay C, et al. Clinical prediction and diagnosis of neurosyphilis in HIV-infected patients with early Syphilis. J Clin Microbiol. 2013;51(12):4060–6.View ArticlePubMedPubMed CentralGoogle Scholar
  65. Marra CM, Maxwell CL, Collier AC, Robertson KR, Imrie A. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. BMC Infect Dis. 2007;7:37.View ArticlePubMedPubMed CentralGoogle Scholar
  66. Marra CM, Tantalo LC, Sahi SK, Maxwell CL, Lukehart SA. CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis. Sex Transm Dis. 2010;37(5):283–7.PubMedPubMed CentralGoogle Scholar
  67. Mothapo KM, Verbeek MM, van der Velden LB, Ang CW, Koopmans PP, van der Ven A, et al. Has CXCL13 an Added Value in Diagnosis of Neurosyphilis? J Clin Microbiol. 2015;53(5):1693–6.View ArticlePubMedPubMed CentralGoogle Scholar
  68. Hu R, Lu C, Lu S, Hu Y, Ma H, Lai W et al. Value of CXCL13 in diagnosing asymptomatic neurosyphilis in HIV-infected patients. Int J STD AIDS 2015.Google Scholar
  69. Snowden JM, Wei C, McFarland W, Raymond HF. Prevalence, correlates and trends in seroadaptive behaviours among men who have sex with men from serial cross-sectional surveillance in San Francisco, 2004-2011. Sex Transm Infect. 2014;90(6):498–504.View ArticlePubMedGoogle Scholar
  70. Truong HM, Kellogg T, Klausner JD, Katz MH, Dilley J, Knapper K, et al. Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting? Sex Transm Infect. 2006;82(6):461–6.View ArticlePubMedPubMed CentralGoogle Scholar
  71. Zablotska IB, Imrie J, Prestage G, Crawford J, Rawstorne P, Grulich A, et al. Gay men’s current practice of HIV seroconcordant unprotected anal intercourse: serosorting or seroguessing? AIDS Care. 2009;21(4):501–10.View ArticlePubMedGoogle Scholar
  72. Brewer TH, Peterman TA, Newman DR, Schmitt K. Reinfections during the Florida syphilis epidemic, 2000-2008. Sex Transm Dis. 2011;38(1):12–7.View ArticlePubMedGoogle Scholar
  73. Cohen SE, Chew Ng RA, Katz KA, Bernstein KT, Samuel MC, Kerndt PR, et al. Repeat syphilis among men who have sex with men in California, 2002-2006: implications for syphilis elimination efforts. Am J Public Health. 2012;102(1):e1–8.View ArticlePubMedPubMed CentralGoogle Scholar
  74. Branger J, van der Meer JT, van Ketel RJ, Jurriaans S, Prins JM. High incidence of asymptomatic syphilis in HIV-infected MSM justifies routine screening. Sex Transm Dis. 2009;36(2):84–5.View ArticlePubMedGoogle Scholar
  75. Bissessor M, Fairley CK, Leslie D, Howley K, Chen MY. Frequent screening for syphilis as part of HIV monitoring increases the detection of early asymptomatic syphilis among HIV-positive homosexual men. J Acquir Immune Defic Syndr. 2010;55(2):211–6.View ArticlePubMedGoogle Scholar
  76. Gray RT, Hoare A, Prestage GP, Donovan B, Kaldor JM, Wilson DP. Frequent testing of highly sexually active gay men is required to control syphilis. Sex Transm Dis. 2010;37(5):298–305.PubMedGoogle Scholar
  77. Tuite AR, Burchell AN, Fisman DN. Cost-effectiveness of enhanced syphilis screening among HIV-positive men who have sex with men: a microsimulation model. PLoS ONE. 2014;9(7), e101240.View ArticlePubMedPubMed CentralGoogle Scholar
  78. Lewis FM, Schillinger JA, Taylor M, Brewer TH, Blank S, Mickey T, et al. Needle in a haystack: the yield of syphilis outreach screening at 5 US sites-2000 to 2007. J Public Health Manag Pract. 2011;17(6):513–21.View ArticlePubMedGoogle Scholar
  79. Silberstein GS, Coles FB, Greenberg A, Singer L, Voigt R. Effectiveness and cost-benefit of enhancements to a syphilis screening and treatment program at a county jail. Sex Transm Dis. 2000;27(9):508–17.View ArticlePubMedGoogle Scholar
  80. Hightow-Weidman L, Beagle S, Pike E, Kuruc J, Leone P, Mobley V, et al. “No one’s at home and they won’t pick up the phone”: using the Internet and text messaging to enhance partner services in North Carolina. Sex Transm Dis. 2014;41(2):143–8.View ArticlePubMedGoogle Scholar
  81. Klausner JD, Wolf W, Fischer-Ponce L, Zolt I, Katz MH. Tracing a syphilis outbreak through cyberspace. JAMA. 2000;284(4):447–9.View ArticlePubMedGoogle Scholar
  82. McFarlane M, Kachur R, Klausner JD, Roland E, Cohen M. Internet-based health promotion and disease control in the 8 cities: successes, barriers, and future plans. Sex Transm Dis. 2005;32(10 Suppl):S60–4.View ArticlePubMedGoogle Scholar
  83. Winetrobe H, Rice E, Bauermeister J, Petering R, Holloway IW. Associations of unprotected anal intercourse with Grindr-met partners among Grindr-using young men who have sex with men in Los Angeles. AIDS Care. 2014;26(10):1303–8.View ArticlePubMedGoogle Scholar
  84. Landovitz RJ, Tseng CH, Weissman M, Haymer M, Mendenhall B, Rogers K, et al. Epidemiology, sexual risk behavior, and HIV prevention practices of men who have sex with men using GRINDR in Los Angeles. California J Urban Health. 2013;90(4):729–39.View ArticlePubMedGoogle Scholar
  85. Su JY, Holt J, Payne R, Gates K, Ewing A, Ryder N. Effectiveness of using Grindr to increase syphilis testing among men who have sex with men in Darwin, Australia. Aust N Z J Public Health 2015.Google Scholar
  86. Peterman TA, Furness BW. Public health interventions to control syphilis. Sex Health 2015.Google Scholar
  87. Stoltey JE, Cohen SE. Syphilis transmission: a review of the current evidence. Sex Health 2015.Google Scholar
  88. Wilson DP, Prestage GP, Gray RT, Hoare A, McCann P, Down I, et al. Chemoprophylaxis is likely to be acceptable and could mitigate syphilis epidemics among populations of gay men. Sex Transm Dis. 2011;38(7):573–9.View ArticlePubMedGoogle Scholar
  89. Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sex Transm Dis. 2015;42(2):98–103.View ArticlePubMedPubMed CentralGoogle Scholar
  90. Pintye J, Baeten JM, Manhart LE, Celum C, Ronald A, Mugo N, et al. Association between male circumcision and incidence of syphilis in men and women: a prospective study in HIV-1 serodiscordant heterosexual African couples. Lancet Glob Health. 2014;2(11):e664–71.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© Tuddenham and Ghanem. 2015

Advertisement